Compared with those who received no hormone treatment, athletes in the two
estrogen treatment groups taken together had significantly better verbal memory and cognitive flexibility scores at the end of six months than their pre-treatment scores, the investigators reported.
Not exact matches
When the researchers evaluated the
estrogen treated
groups separately versus no
treatment, they found significantly greater improvement in certain cognitive tests only in the
group that received transdermal
estrogen.
Study participants were randomly assigned to one of three
treatment groups for six months: (1) oral estradiol and progesterone at a dose similar to that in many birth control pills (16 participants); (2) transdermal estradiol, better known as the
estrogen patch, at a physiological replacement dose with cyclic progesterone (13 athletes); or (3) no
estrogen (19 subjects).
The other
group, made up of 202 men, received the same
treatment as in
group 1 but also received anastrozole (Arimidex, AstraZeneca) to block conversion of testosterone to
estrogen.
These results, also presented at the 2015 European Cancer Congress (ECC2015, abstract # 5BA) today, which involve the
group of 1,626 patients with a Recurrence Score between 0 and 10, demonstrated that 99.3 percent of node - negative,
estrogen receptor (ER)- positive, human epidermal growth factor receptor 2 (HER2)- negative patients who met accepted guidelines for recommending chemotherapy in addition to hormonal therapy, had no distant recurrence at five years after
treatment with hormonal therapy alone.